Optimizing Antimicrobial Therapy for Gram-Positive Bloodstream Infections in Patients on Hemodialysis

Advances in Chronic Kidney Disease

Volumn 13, Issue 3, 2006, Pages 259-270

  Pai, Amy Barton ^a   Pai, Manjunath P ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Antimicrobials; Gram positive; Hemodialysis; Pharmacodynamics; Pharmacokinetics; Resistance

Indexed keywords

AMINOETHOXYACETIC ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CEFEPIME; CEPHALOSPORIN; COTRIMOXAZOLE; DAPTOMYCIN; DRUG METABOLITE; GENTAMICIN; HYDROXYETHYL GLYCINE; LINEZOLID; MINOCYCLINE; NAFCILLIN; OXACILLIN; PENICILLIN G; PNU 142300; PNU 142586; SEROTONIN UPTAKE INHIBITOR; TETRACYCLINE; TOBRAMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANEMIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BIOFILM; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENDOCARDITIS; ENTEROCOCCUS; ENZYME BLOOD LEVEL; GRAM POSITIVE BACTERIUM; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MYALGIA; MYOPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OPTIC NERVE DISEASE; OSTEOMYELITIS; OTOTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RED MAN SYNDROME; SEIZURE; SEROTONIN SYNDROME; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; THROMBOCYTOPENIA; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 33745408362     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2006.04.005     Document Type: Article

References (60)

1. Lee T., Barker J., and Allon M. Tunneled catheters in hemodialysis patients. Reasons and subsequent outcomes. Am J Kidney Dis 46 (2005) 501-508
2. Taylor G., Gravel D., Johnston L., et al. Prospective surveillance for primary bloodstream infections occurring in Canadian hemodialysis units. Infect Control Hosp Epidemiol 23 (2002) 716-720
3. Marr K.A. Staphylococcus aureus bacteremia in patients undergoing hemodialysis. Semin Dial 13 (2000) 23-29
4. Fowler V., Miro J., Hoen B., et al. Staphylococcus aureus endocarditis. A consequence of medical progress. JAMA 293 (2005) 3012-3021
5. Engemann J., Friedman J., Reed S., et al. Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. Infect Control Hosp Epidemiol 26 (2005) 534-539
6. Foley R., Guo H., Snyder J., et al. Septicemia in the United States dialysis population, 1991 to 1999. J Am Soc Nephrol 15 (2004) 1038-1045
7. USRDS 2003 Annual Data Report. Atlas of End-Stage Renal Disease in the United States (2003), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
8. Tokars J., Miller E., and Stein G. New national surveillance system for hemodialysis-associated infections. Initial results. Am J Infect Control 30 (2002) 288-295
9. Klevens R., Edwards J., Tenover F., et al. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 42 (2006) 389-391
10. Wertheim H., Melles D., Vos M., et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 5 (2005) 751-762
11. Cosgrove S.E., Carroll K.C., and Perl T.M. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 39 (2004) 539-545
12. Gemmell C.G. Glycopeptide resistance in Staphlyococcus aureus. Is it a real threat?. J Infect Chemther 10 (2004) 69-75
13. http://www.michigan.gov/mdchlab Accessed 06-Jan-2006
14. Peeters M.J., and Sarria J.C. Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. Am J Med Sci 330 (2005) 102-104
15. Hayden M., Rezai K., Hayes R., et al. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 43 (2005) 5285-5287
16. Raad I., Alrahwan A., and Rolston K. Staphylococcus epidermidis. Emerging resistance and need for alternative agents. Clin Infect Dis 26 (1998) 1182-1187
17. Dopirak M., Hill C., Oleksiw M., et al. Surveillance of hemodialysis-associated primary bloodstream infections. The experience of ten hospital-based centers. Infect Control Hosp Epidemiol 23 (2002) 721-724
18. Fux C., Uehlinger D., Bodmer T., et al. Dynamics of hemodialysis catheter colonization by coagulase-negative staphylococci. Infect Control Hosp Epidemiol 26 (2005) 567-574
19. Donlan R.M., and Costerton J.W. Biofilms. Survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15 (2002) 167-193
20. Hayden M.K. Insights into the epidemiology and control of infection with vancomycin-resistant enterococci. Clin Infect Dis 31 (2000) 1058-1065
21. Tokars J., Frank M., Alter M., et al. National surveillance of dialysis-associated diseases in the United States, 2000. Semin Dial 15 (2002) 162-171
22. Craig W.A. Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 17 (2003) 479-501
23. Nicolau D.P. Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. J Infect Chemother 9 (2003) 292-296
24. Craig W.A. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 22 (1995) 89-96
25. Gentry C., Rodvold K., Novak R., et al. Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy 17 (1997) 990-997
26. Sowinski K., Mueller B., Grabe D., et al. Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. Am J Kidney Dis 37 (2001) 766-776
27. Craig W.A., and Ebert S.C. Killing and regrowth of bacteria in vitro. A review. Scand J Infect Dis 74 suppl (1990) 63-70
28. Product Information. Maxipime (cefepime HCl) (2003), Bristol-Meyers Squibb, Princeton, NJ
29. Tam V., McKinnon P., Akins R., et al. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother 57 (2003) 1853-1861
30. Schmaldienst S., Traunmuller F., Burgmann H., et al. Multiple-dose pharmacokinetics of cefepime in long-term hemodialysis withhigh-flux membranes. Eur J Clin Pharmacol 56 (2000) 61-64
31. Wong K., Chan W., Chan Y., et al. Cefepime-related neurotoxicity in a haemodialysis patient. Nephrol Dial Transplant 14 (1999) 2265-2266
32. Larsson A., Walker K., Raddatz J., et al. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J Antimicrob Chemother 38 (1996) 589-597
33. Rello J., Sole-Violan J., Sa-Borges M., et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 33 (2005) 1983-1987
34. Matzke G., McGory R., Halstenson C., et al. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 25 (1984) 433-437
35. Foote E., Dreitlein W., Staewrad C., et al. Pharmacokinetics of vancomycin administered during high flux hemodialysis. Clin Nephrol 50 (1998) 51-55
36. Mason N., Neudeck B., Welage L., et al. Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers. Post dislysis versus intradialytic administration. Clin Nephrol 60 (2003) 96-104
37. Pai A.B., and Pai M. Vancomycin dosing in high flux hemodialysis. A limited-sampling algorithm. Am J Health Syst Pharm 61 (2004) 1812-1816
38. Ariano R., Fine A., Sitar D., et al. Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis. Am J Kidney Dis 46 (2005) 681-687
39. Pai M.P., Mercier R.C., and Koster S.A. Epidemiology of vancomycin-induced thrombocytopenia in patients receiving home intravenous infusion therapy. Ann Pharmacother 40 (2006) 224-228
40. Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin North Am 17 (2003) 503-528
41. Graham J.C., and Gould F.K. Role of aminoglycosides in the treatment of bacterial endocarditis. J Antimicrob Chemother 49 (2002) 437-444
42. Vercaigne L.M., Ariano R.E., and Zacharias J.M. Bayesian pharmacokinetics of gentamicin in a haemodialysis population. Clin Pharmacokinet 43 (2004) 205-210
43. Chandna S.M., and Farrington K. Residual renal function. Considerations on its importance and preservation in dialysis patients. Semin Dial 17 (2004) 196-201
44. Black F.O., Pesznecker S., and Stallings V. Permanent gentamicin vestibulotoxicity. Otol Neurotol 25 (2004) 559-569
45. Stalker D.J., and Jungbluth G.L. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 42 (2003) 1129-1140
46. Slatter J., Stalker D., Feenstra K., et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C] linezolid to healthy human subjects. Drug Metab Dispos 29 (2001) 1136-1145
47. Brier M., Stalker D., Aronoff G., et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 47 (2003) 2775-2780
48. Fiaccadori E., Maggiore U., Rotelli C., et al. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med 32 (2004) 2437-2442
49. Andes D., van Ogtrop M., Peng J., et al. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 46 (2002) 3484-3489
50. Shorr A.F., Kunkel M.J., and Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemeia. A pooled analysis of randomized studies. J Antimicrob Chemother 56 (2005) 923-929
51. Wu V., Wang Y., Wang C., et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 42 (2006) 66-72
52. Bressler A., Zimmer S., Gilmore J., et al. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 4 (2004) 528-531
53. Bergeron L., Boule M., and Perreault S. Serotonin toxicity associated with concomitant use of linezolid. Ann Pharmacother 39 (2005) 956-961
54. Pai M.P., Rodvold K.A., Schrekenberger P.C., et al. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clin Infect Dis 35 (2002) 1269-1272
55. Schriever C., Fernandez C., Rodvold K., et al. Daptomycin. A novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm 62 (2005) 1145-1158
56. Dvorchik B., Arbeit R., Chung J., et al. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 48 (2004) 2799-2807
57. Safdar N., Andes D., and Craig W.A. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 48 (2004) 63-68
58. Huang V., and Rybak M.J. Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function. J Antimicrob Chemother 57 (2006) 116-121
59. Oleson Jr. F., Berman C., Kirkpatrick J., et al. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 44 (2000) 2948-2953
60. Long J.K., Choueiri T.K., Hall G.S., et al. Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clin Proc 80 (2005) 1122-1125